Apremilast as an Off-Label Therapeutic Agent
dc.contributor.author | Marson, Justin | |
dc.contributor.author | Lebwohl, Mark | |
dc.date.accessioned | 2023-03-03T19:41:26Z | |
dc.date.available | 2023-03-03T19:41:26Z | |
dc.date.issued | 2021-05-17 | |
dc.identifier.citation | Marson, J., & Lebwohl, M. (2021). Apremilast as an Off-Label Therapeutic Agent: A Comprehensive Review of Safety and Efficacy Data in the Literature for Combination Therapy and Inflammatory Dermatoses. SKIN The Journal of Cutaneous Medicine, 5(3), 203–227. DOI: 10.25251/skin.5.3.2 | en_US |
dc.identifier.eissn | 2574-1624 | |
dc.identifier.doi | 10.25251/skin.5.3.2 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12648/8483 | |
dc.description.abstract | Objective: To review the literature regarding the efficacy and safety of off-label use of apremilast in combination therapies for psoriasis and psoriatic arthritis and for other currently off-label inflammatory dermatoses. Methods: The Medline database was queried for all relevant articles published between 2014 and 2021 using exploded MeSH terms and keywords pertaining to the following themes: off-label, combination therapy, biologics, biologic therapy, methotrexate, and systemic psoriasis therapy. The Boolean term “AND” was used to find the intersection of these themes with the term “apremilast.” Results: 8 case series and 6 case reports investigated the use of apremilast in combination therapy for psoriasis and psoriatic arthritis. Addition of apremilast improved PASI scores by 31.8-77.4% among case series and 80-100% among case reports with adverse effects primarily consisting of gastrointestinal symptoms. 5 randomized-control trials (RCT), 9 open-label trials, 18 case series, and 30 case reports investigated the use of apremilast for off-label dermatoses. In RCTs, apremilast showed potential efficacy for atopic dermatitis and hidradenitis suppurativa. Open-label trials found apremilast efficacious for atopic dermatitis, allergic contact dermatitis, chronic pruritus, cutaneous sarcoidosis, discoid lupus erythematosus, hidradenitis suppurativa, lichen planus, prurigo nodularis, rosacea, and vitiligo. Limitations: Small sample size and short follow up duration for available randomized-control and open-label trials. Current data from case series/reports potentially limits generalizability of findings. Conclusion: Apremilast's safety profile makes it a potential efficacious, non-biologic systemic agent for monotherapy and combination therapy for a wide range of inflammatory dermatoses. | en_US |
dc.language.iso | N/A | en_US |
dc.publisher | National Society for Cutaneous Medicine | en_US |
dc.relation.url | https://jofskin.org/index.php/skin/article/view/1239 | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Apremilast | en_US |
dc.subject | Inflammation | en_US |
dc.subject | PDE-4 Inhibitor, | en_US |
dc.subject | Combination Therapy | en_US |
dc.subject | Off-label | en_US |
dc.title | Apremilast as an Off-Label Therapeutic Agent | en_US |
dc.type | Article/Review | en_US |
dc.source.journaltitle | SKIN The Journal of Cutaneous Medicine | en_US |
dc.source.volume | 5 | |
dc.source.issue | 3 | |
dc.source.beginpage | 203 | |
dc.source.endpage | 227 | |
dc.description.version | VoR | en_US |
refterms.dateFOA | 2023-03-03T19:41:26Z | |
dc.description.institution | SUNY Downstate | en_US |
dc.description.department | Dermatology | en_US |
dc.description.degreelevel | N/A | en_US |